Risk-adapted use of intravesical chemotherapy

BJU International

Volumn 102, Issue 9B, 2008, Pages 1247-1253

  Lerner, Seth P ^a   Au, Jessie L S ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APAZIQUONE; BCG VACCINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; INTERLEUKIN 2; MITOMYCIN C; PIRARUBICIN; SMALLPOX VACCINE; THIOTEPA; VALRUBICIN; VIRUS VECTOR;

ADD ON THERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SINGLE DRUG DOSE; SKIN MANIFESTATION; SLOW DRUG RELEASE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS;

EID: 54149111978     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07967.x     Document Type: Review

References (75)

1. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998 22 : 1435 48
2. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002 60 : 315 9
3. Kamat AM, Gee JR, Dinney CP et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006 175 : 881 5
4. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000 164 : 680 4
5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008 54 : 303 14. Apr 30 Epub ahead of print
6. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 49 : 466 5
7. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res 2008 25 (7 1500 10. March 28 Epub
8. MRC Working Party on Urological Cancer. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. Br J Urol 1985 57 : 680 5
9. Okamura K, Ono Y, Kinukawa T et al. Randomized study of single early instillation of (2′R) -4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002 94 : 2363 8
10. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993 149 : 749 52
11. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999 161 : 1120 3
12. Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996 155 : 1233 8
13. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 1983 129 : 505 9
14. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004 171 : 2186 90. quiz 435
15. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis). 2007 update. J Urol 2007 178 : 2314 30
16. Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993 32 : 255 62
17. Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001 93 : 597 604
18. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007 52 : 1123 9
19. Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995 153 : 934 41
20. Sylvester RJMA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002 168 : 1964 70
21. Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004 27 : 522 8
22. Okeke AA, Probert JL, Gillatt DA, Schwaibold H. Is intravesical chemotherapy for superficial bladder cancer still justified? BJU Int 2005 96 : 763 7
23. Hinotsu S, Akaza H, Isaka S et al. Sustained prophylactic effect of intravesical bacille Calmette-Guerin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006 67 : 545 9
24. Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006 7 : 43 51
25. Ojea A, Nogueira JL, Solsona E et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007 52 : 1398 406
26. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000 163 : 761 7
27. Gacci M, Bartoletti R, Cai T et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int 2006 76 : 106 11
28. Gunelli R, Bercovich E, Nanni O et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer 2007 97 : 1499 504
29. Maymi JL, Saltsgaver N, O'Donnell MA. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 2006 175 (Suppl.): 271, Abstract 840
30. van der Meijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004 46 : 65 71
31. Hyaluronidase (Vitrase): ISTA hyaluronidase - ISTA pharmaceuticals. Drugs R D 2003 4 : 194 7
32. Chen D, Song D, Wientjes MG, Au JL. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 2003 9 : 363 9
33. Grabnar I, Bogataj M, Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 2003 256 : 167 73
34. Hashimoto H, Tokunaka S, Sasaki M, Nishihara M, Yachiku S. Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder. Urol Res 1992 20 : 233 6
35. Kos MK, Bogataj M, Veranic P, Mrhar A. Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan. Biol Pharm Bull 2006 29 : 1685 91
36. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005 140 : 585 97
37. Sant GR. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis. Urology 1987 29 : 17 21
38. Schoenfeld RH, Belville WD, Jacob WH et al. The effect of dimethyl sulfoxide on the uptake of cisplatin from the urinary bladder of the dog: a pilot study. J Am Osteopath Assoc 1983 82 : 570 3
39. See WA, Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992 84 : 510 5
40. Sasaki M, Hashimoto H, Yachiku S. [Studies on enhancement of drug absorption through the bladder mucosa]. Nippon Hinyokika Gakkai Zasshi 1994 85 : 1353 62
41. Hobarth K, Maier U, Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol 1992 21 : 206 10
42. Horn Y, Eidelman A, Walach N, Waron M, Barak F. Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase. J Surg Oncol 1985l 28 : 304 7
43. Maier U, Baumgartner G. Mitomycin C plasma levels after intravesical instillation with and without hyaluronidase. J Urol 1986 135 : 845 6
44. Brausi M, Campo B, Pizzocaro G et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 1998 51 : 506 9
45. Di Stasi SM, Giannantoni A, Massoud R et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 1999 59 : 4912 8
46. Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003 170 : 777 82
47. Di Stasi SM, Vespasiani G, Giannantoni A, Massoud R, Dolci S, Micali F. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 1997 57 : 875 80
48. Corry PM, Robinson S, Getz S. Hyperthermic effects on DNA repair mechanisms. Radiology 1977 123 : 475 82
49. Herman TS, Teicher BA, Jochelson M, Clark J, Svensson G, Coleman CN. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia 1988 4 : 143 58
50. Moskovitz B, Meyer G, Kravtzov A et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005 16 : 585 9
51. Le Visage C, Rioux-Leclercq N, Haller M, Breton P, Malavaud B, Leong K. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 2004 171 : 1324 9
52. Tyagi P, Li Z, Chancellor M, De Groat WC, Yoshimura N, Huang L. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 2004 21 : 832 7
53. Ye Z, Chen J, Zhang X et al. Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. J Tongji Med Univ 2001 21 : 145 8
54. Leakakos T, Ji C, Lawson G, Peterson C, Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003 51 : 445 50
55. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005 173 : 604 9
56. Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 2005 66 : 224 9
57. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000 6 : 4422 31
58. Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep 2001 8 : 955 64
59. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996 155 : 753 6
60. Dose-escalation study of CG0070 for bladder cancer after BCG (Bacillus Calmette-Guerin) Failure. NCI trial #V-0046
61. Ramesh N, Ge Y, Ennist DL et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor - armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006 12 : 305 13
62. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HJ, Mulholland SG, Lattime EC. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001 166 : 1291 5
63. Kuball J, Wen SF, Leissner J et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002 20 : 957 65
64. Pagliaro LC, Keyhani A, Williams D et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003 21 : 2247 53
65. Trial. A phase I study of the safety and tolerability of intravesical administration of SCH 721015 in patients with transitional cell carcinoma of the bladder. #2005-0580
66. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000 7 : 31 4
67. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 2000 7 : 844 51
68. Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 2005 66 : 461 6
69. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004 32 : e149
70. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003 9 : 1291 300
71. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002 20 : 1006 10
72. Hou JQ, He J, Wang XL, Wen DG, Chen ZX. Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Chin Med J (Engl) 2006 119 : 1734 9
73. Ning S, Fuessel S, Kotzsch M et al. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004 25 : 1065 71
74. Nogawa M, Yuasa T, Kimura S et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005 115 : 978 85
75. Zou L, Zhang P, Luo C, Tu Z. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 2006 57 : 328 34